Ospedale Umberto I di Torino Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2020
NCT04390061
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma | Città della Salute e della Scienza di Torino University Hospital | OA Ordine Mauriziano - Torino, Italy | Ospedale Umberto I di Torino | Rete Oncologica Piemonte, Valle d'Aosta

Active Ingredients

Drugs in Phase 2 Trials (2)

hydroxychloroquine (plaquenil) (1 trial)

tofacitinib (xeljanz) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lung Diseases, Interstitial (Phase 2)

Pneumonia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2